CoChat
Sign Up
Cited by 2,420Cervical Cancer and HPV ResearchReproductive tract infections researchWomen's cancer prevention and management

Human papillomavirus and cervical cancer

Open access
Burd, Eileen M.·2003·Clinical Microbiology Reviews
DOI 10.1128/cmr.16.1.1-17.2003PMC PMC145302
Open this paper in CoChat — free account

Abstract

SUMMARY: Of the many types of human papillomavirus (HPV), more than 30 infect the genital tract. The association between certain oncogenic (high-risk) strains of HPV and cervical cancer is well established. Although HPV is essential to the transformation of cervical epithelial cells, it is not sufficient, and a variety of cofactors and molecular events influence whether cervical cancer will develop. Early detection and treatment of precancerous lesions can prevent progression to cervical cancer. Identification of precancerous lesions has been primarily by cytologic screening of cervical cells. Cellular abnormalities, however, may be missed or may not be sufficiently distinct, and a portion of patients with borderline or mildly dyskaryotic cytomorphology will have higher-grade disease identified by subsequent colposcopy and biopsy. Sensitive and specific molecular techniques that detect HPV DNA and distinguish high-risk HPV types from low-risk HPV types have been introduced as an adjunct to cytology. Earlier detection of high-risk HPV types may improve triage, treatment, and follow-up in infected patients. Currently, the clearest role for HPV DNA testing is to improve diagnostic accuracy and limit unnecessary colposcopy in patients with borderline or mildly abnormal cytologic test results.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/cmr.16.1.1-17.2003

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • 14 anogenital HPVs are categorized as high-risk HPV types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68).

    “14 anogenital HPVs have been categorized as high-risk HPV (hrHPV) types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) [3].”

    From Comparison of Seegene Anyplex II HPV28 assay with BD Onclarity HPV assay for human papillomavirus genotyping (2022) · cites this paper as [3]

    The Introduction categorizes all 14 listed types as high-risk, and the HPV DNA Detection section lists those exact 14 as targets of high-risk type-specific PCR assays. But the Introduction also includes HPV 34 and 70 in its high-risk category, so it does not support a total of only 14 high-risk types. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • HPV16 and HPV18 constitute more than 70% of cervical cancers.

    “Although HPV16 and HPV18 constitute >70% of cervical cancers [3, 22]”

    From Comparison of Seegene Anyplex II HPV28 assay with BD Onclarity HPV assay for human papillomavirus genotyping (2022) · cites this paper as [3]

    The Introduction says HPV16 accounts for about half of cervical cancer cases in the United States and Europe, while HPV18, HPV31, and HPV45 together account for another 25–30%. It does not assign that additional share to HPV18 alone or establish that HPV16 and HPV18 together exceed 70%. (LLM, conf=0.89)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 130

  1. Cervical cancer is the third most common cancer in women in the United States, preceded by skin cancer and breast cancer as the first and second most common causes, respectively (93). In developing countries, cervical cancer is often the most common cancer in women and may constitute up to 25% of all female cancers (45). Cervical cancer is preceded only by breast cancer as the most common cause of death from cancer in women worldwide (54). The link between genital HPV infections and cervical cancer was first demonstrated in the early 1980s by Harold zur Hausen, a German virologist. Since then, the link between HPV and cervical squamous cell carcinoma has become well established. The magnitude of the association between HPV and cervical squamous cell carcinoma is higher than that for the association between smoking and lung cancer (37). In 1996, the World Health Association, along with the European Research Organization on Genital Infection and Neoplasia and the National Institutes of Health Consensus Conference on Cervical Cancer, recognized HPV as an important cause of cervical cancer. Scientists have identified about 30 HPV types that are spread through sexual contact and infect primarily the cervix, vagina, vulva, penis, and anus. Of these, four are most often found within the malignant cells of cervical cancers, with type 16 accounting for about half of the cases in the United States and Europe and types 18, 31, and 45 accounting for an additional 25 to 30% of cases (45). HPV has been implicated in 99.7% of cervical squamous cell cancer cases worldwide (124). Adenocarcinomas of the cervix are also related to HPV, but the correlation is less pronounced and is age dependent (3). In women younger than 40 years, HPV was present in 89% of adenocarcinomas, whereas in women aged 60 years and older, HPV was observed in only 43%.
  2. Evidence-based consensus guidelines for the management of cervical cytological abnormalities and cervical cancer precursors were developed at the American Society for Colposcopy and Cervical Pathology (ASCCP) Consensus Conference in September 2001. The new Bethesda 2001 terminology for reporting cervical cytology results, fluid-based cytology methods, molecular methods for detecting high-risk HPV types, data from the ALTS trial, and cost analyses were all taken into consideration in development of the guidelines. Recommended management schemes for all grades of cervical cytology abnormalities are posted on the ASCCP website at http://www.asccp.org.
  3. [1]Adam, E., Z. Berkova, Z. Daxnerova, J. Icenogle, W. C. Reeves, and R. H. Kaufman. 2000. Papillomavirus detection: demographic and behavioral characteristics influencing the identification of cervical disease. Am. J. Obstet. Gynecol. 182:257-264. [DOI] [PubMed] [Google Scholar]
  4. [2]Allen, M., M. Kalantari, N. Ylitalo, B. Pettersson, B. Hagmar, L. Scheibenplug, B. Johansson, U. Petterson, and U. Gyllensten. 1996. HLA DQ-DR haplotype and susceptibility to cervical carcinoma: indications of increased risk for development of cervical carcinoma in individuals infected with HPV 18. Tissue Antigens 48:32-37. [DOI] [PubMed] [Google Scholar]
  5. [3]Andersson, S., E. Rylander, B. Larsson, A. Strand, C. Silfversvard, and E. Wilander. 2001. The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur. J. Cancer 37:246-250. [DOI] [PubMed] [Google Scholar]
  6. [4]Andrei, G., R. Snoeck, J. Piette, P. Delvenne, and E. DeClercq. 1998. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol. Res. 10:523-531. [PubMed] [Google Scholar]
  7. [5]Apple R. J., T. M. Becker, C. M. Wheeler, and H. A. Erlich. 1995. Comparison of human leukocyte antigen DR-DQ disease associations found with cervical dysplasia and invasive cervical carcinoma. J. Natl. Cancer Inst. 87:427-436. [DOI] [PubMed] [Google Scholar]
  8. [6]Apt, D., R. M. Watts, G. Suske, and U. Bernard. 1996. High Sp1/Sp3 ratios in epithelial cells during epithelial differentiation and cellular transcription correlate with the activation of the HPV-16 promoter. Virology 224:281-291. [DOI] [PubMed] [Google Scholar]
  9. [7]Austin, R. M., and I. Ramzy. 1998. Increased detection of epithelial cell abnormalities by liquid-based gynecologic cytology preparations. Acta Cytol. 42:178-184. [DOI] [PubMed] [Google Scholar]
  10. [8]Baker, T. S., W. W. Newcomb, N. H. Olson, L. M. Cowsert, C. Olson, and J. C. Brown. 1991. Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys. J. 60:1445-1456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. [9]Beaudenon, S., D. Kremsdorf, O. Croissant, S. Jablonska, S. Wain-Hobson, and G. Orth. 1986. A novel type of human papillomavirus associated with genital neoplasias. Nature 321:246-249. [DOI] [PubMed] [Google Scholar]
  12. [10]Beaudenon, S., D. Kremsdorf, S. Obalek, S. Jablonska, G. Pehau-Amaudet, O. Croissant, and G. Orth. 1987. Plurality of genital human papillomaviruses: characterization of two new types with distinct biological properties. Virology 161:373-384. [DOI] [PubMed] [Google Scholar]
  13. [11]Bedell, M. A., J. B. Hudson, T. R. Golub, M. E. Turyk, M. Hosken, G. D. Wilbanks, and L. A. Laimins. 1991. Amplification of human papillomavirus genomes in vitro is dependent on epithelial differentiation. J. Virol. 65:2254-2260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. [12]Bonnez, W., and R. C. Reichman. 2000. Papillomaviruses, p. 1630-1640. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 5th ed. Churchill Livingston, Philadelphia, Pa.
  15. [13]Bontkes, H. J., M. Van Duin, T. D. deGruijl, M. F. Duggan-Keen, J. M. Walboomers, M. J. Stukart, R. H. Vereheijen, T. J. Helmerhorst, C. J. Meijer, R. J. Scheper, F. R. Stevens, P. A. Dyer, P. Sinnott, and P. L. Stern. 1998. HPV 16 infection and progression of cervical intraepithelial neoplasia: analysis of HLA polymorphism and HPV 16 E6 sequences variants. Int. J. Cancer 78:166-171. [DOI] [PubMed] [Google Scholar]
  16. [14]Bontkes, H. J., T. D. deGruijl, J. M. Walboomers, J. T. Schiller, J. Dillner, T. J. Helmerhorst, R. H. Vereheijen, R. J. Scheper, and C. J. Meijer. 1999. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. J. Gen. Virol. 80:409-417. [DOI] [PubMed] [Google Scholar]
  17. [15]Bosch, F., M. M. Manos, N. Munoz, M. Sherman, A. M. Jansen, J. Peto, M. H. Schiffman, V. Moreno, R. Kurman, K. V. Shah, and International Biological Study on Cervical Cancer (IBSCC) Study Group. 1995. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst. 87:796-802. [DOI] [PubMed] [Google Scholar]
  18. [16]Brisson, J, K. Morin, M. Fortier, M. Roy, C. Bouchard, J. Leclerc, A. Christen, C. Guimont, F. Penault, and A. Meisels. 1994. Risk factors for cervical intraepithelial neoplasia:differences between low and high-grade lesions. Am. J. Epidemiol. 40:700-710. [DOI] [PubMed] [Google Scholar]
  19. [17]Broder, S. 1992. The Bethesda System for reporting cervical/vaginal cytologic diagnoses—report of the 1991 Bethesda Workshop. JAMA 267:1892. [PubMed] [Google Scholar]
  20. [18]Burk, R. D., P. Kelly, J. Feldman, J. Bromberg, S. H. Vermund, J. A. Deltovitz, and S. H. Landesman. 1996. Declining presence of cervicovaginal human papilllomavirus infection with age is independent of other risk factors. Sex. Transm. Dis. 23:333-341. [DOI] [PubMed] [Google Scholar]
  21. [19]Calore, E. E., S. M. M. Pereira, and M. J. Cavaliere. 2001. Progression of cervical lesions in HIV-seropositive women: a cytological study. Diagn. Cytopathol. 24:117-119. [DOI] [PubMed] [Google Scholar]
  22. [20]Cates, W., and the American Social Health Association Panel. 1999. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. Sex. Transm. Dis. 26:S2-S7. [DOI] [PubMed] [Google Scholar]
  23. [21]Chan, P. K., M. Y. Chan, W. W. Li, D. P. Chan, J. L. Cheung, and A. F. Cheung. 2001. Association of human beta-herpesviruses with the development of cervical cancer:bystanders or cofactors? J. Clin. Pathol. 54:48-53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. [22]Chang, Y. E., and L. A. Laimins. 2000. Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J. Virol. 74:4174-4182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. [23]Chen, M., N. Popescu, C. Woodworth, Z. Berneman, M. Corbellino, P. Lusso, D. V. Ablashi, and J. A. DiPaolo. 1994. Human herpesvirus 6 infects cervical epithelial cells and transactivates human papillomavirus gene expression. J. Virol. 68:1173-1178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. [24]Chua, K. L., and A. Hjerpe. 1996. Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. Cancer 77:121-127. [DOI] [PubMed] [Google Scholar]
  27. [25]Clinical Laboratory Improvement Amendments of 1988. 1988. P.L. 100-578. Congress. Rec. 134:3828-3863. [Google Scholar]
  28. [26]Coker, A. L., R. B. Russell, S. M. Bond, L. Pirisi, Y. Liu, M. Mane, N. Kokorina, T. Gerasimova, and P. L. Hermonat. 2001. Adeno-associated virus is associated with a lower risk of high-grade cervical neoplasia. Exp. Mol. Pathol. 70: 83-89. [DOI] [PubMed]
  29. [27]Conrad-Stöppler, M. C., K. Ching, H. Stöppler, K. Clancy, R. Schlegle, and J. Icenogle. 1996. Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J. Virol. 70:6987-6993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. [28]Cubie, H. A., A. L. Seagar, G. J. Beattie, S. Monaghan, and A. R. W. Williams. 2000. A longitudinal study if HPV detection and cervical pathology in HIV infected women. Sex. Transm. Infect. 76:257-261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. [29]Davey, D. D., S. Naryskin., M. L. Nielsen, and T. S. Kline. 1994. Atypical squamous cells of undetermined significance: interlaboratory comparison and quality assurance monitors. Diagn. Cytopathol. 11:390-396. [DOI] [PubMed] [Google Scholar]
  32. [30]DeVillez, R. L., and C. S. Stevens. 1980. Bowenoid papulosis of the genitalia. A case progressing to Bowen's disease. J. Am. Acad. Dermatol. 3:149-152. [DOI] [PubMed] [Google Scholar]
  33. [32]Dong, X.-P., F. Stubenrauch, E. Beyer-Finkler, and H. Pfister. 1994. Prevalence of deletions of YY1-binding sites in episomal HPV 16 DNA from cervical cancers. Int. J. Cancer 58:803-808. [DOI] [PubMed] [Google Scholar]
  34. [33]Evander, M., I. H. Frazer, E. Payne, Y. M. Qui, K. Hengst, and N. A. McMillan. 1997. Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J. Virol. 71:2449-2456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. [34]Favre, M. 1975. Structural polypeptides of rabbit, bovine, and human papillomaviruses. J. Virol. 15:1239-1247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. [35]Flores, E. R., and P. F. Lambert. 1997. Evidence for a switch in the mode of human papillomavirus type 16 DNA replication during the viral life cycle. J. Virol. 71:7167-7179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. [36]Flores, E. R., B. L. Allen-Hoffman, D. Lee, C. A. Sattler, and P. F. Lambert. 1999. Establishment of the human papillomavirus type 16 (HPV-16) life cycle in an immortalized human foreskin keratinocyte cell line. Virology 262:344-354. [DOI] [PubMed] [Google Scholar]
  38. [37]Franco, E. L. 1995. Cancer causes revisited:human papillomavirus and cervical neoplasia. J. Natl. Cancer Inst. 87:779-780. [DOI] [PubMed] [Google Scholar]
  39. [38]Fuchs, P. G., F. Girardi, and H. Pfister. 1988. Human papillomavirus DNA in normal, metaplastic, preneoplastic and neoplastic epithelia of the cervix uteri. Int. J. Cancer 41:41-45. [DOI] [PubMed] [Google Scholar]
  40. [39]Giannoudis, A., and C. S. Herrington. 2001. Human papillomavirus variants and squamous neoplasia of the cervix. J. Pathol. 193:295-302. [DOI] [PubMed] [Google Scholar]
  41. [40]Gilbert, D. M., and S. N. Cohen. 1987. Bovine papillomavirus plasmids replicate randomly in mouse fibroblasts throughout S phase of the cell cycle. Cell 50:59-68. [DOI] [PubMed] [Google Scholar]
  42. [41]Giroglu, T., L. Florin, F. Schäfer, R. E. Streek, and M. Sapp. 2001. Human papillomavirus infection requires cell surface heparan sulfate. J. Virol. 75:1565-1570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. [42]Gissmann, L., L. Wolnik, H. Ikenberg, U. Koldovsky, H. G. Schnurch, and H. zur Hausen. 1983. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc. Natl. Acad. Sci. USA 80:560-563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. [43]Gonzalez, D. I., C. M. Zahn, M. G. Retzloff, W. F. Moore, E. R. Kost, and R. R. Snyder. 2001. Recurrence of dysplasia after loop electrosurgical excision procedures with long-term follow-up. Am. J. Obstet. Gynecol. 184:315-321. [DOI] [PubMed] [Google Scholar]
  45. [44]Halbert, C. L., G. W. Demers, and D. A. Galloway. 1991. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol. 65:473-478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. [45]Harro, C. D., Y.-Y. S. Pang, R. B. S. Roden, A. Hildesheim, Z. Wang, M. J. Reynolds, T. C. Mast, R. Robinson, B. R. Murphy, R. A. Karron, J. Dillner, J. T. Schiller, and D. R. Lowy. 2001. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93:284-292. [DOI] [PubMed] [Google Scholar]
  47. [46]Hildesheim, A., M. Schiffman, C. Bromley, S. Wacholder, R. Herrero, A. C. Rodriuez, M. C. Bratti, M. E. Sherman, U. Scarpidis, Q.-Q. Lin, M. Terai, R. L. Bromley, K. Buetow, R. J. Apple, and R. D. Burk. 2001. Human papillomavirus type 16 variants and risk of cervical cancer. J. Natl. Cancer Inst. 93:315-318. [DOI] [PubMed] [Google Scholar]
  48. [47]Ho, G. Y., R. Bierman, L. Beardsley, C. J. Chang, and R. D. Burk. 1998. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 338:413-428. [DOI] [PubMed] [Google Scholar]
  49. [48]Holowaty, P., A. B. Miller, T. Rohan, and T. To. 1999. Natural dysplasia of the uterine cervix. J. Natl. Cancer Inst. 91:252-258. [DOI] [PubMed] [Google Scholar]
  50. [49]Howell, L. P., R. L. Davis, T. I. Belk, R. Agdigos, and J. Lowe. 1998. The AutoCyte preparation system for gynecologic cytology. Acta Cytol. 42:171-177. [DOI] [PubMed] [Google Scholar]
  51. [50]Hummel, M., J. B. Hudson, and L. A. Laimins. 1992. Differentiation-induced and constitutive transcription of human papillomavirus type 31b in cell lines containing viral episomes. J. Virol. 66:6070-6080. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. [51]Hutchinson, M. L., L. M. Isenstein, A. Goodman, A. A. Hurley, K. L. Douglass, K. K. Mui, F. W. Patten, and D. J. Zahniser. 1994. Homogeneous sampling accounts for increased diagnostic accuracy using the ThinPrep Processor. Am. J. Clin. Pathol. 101:215-219. [DOI] [PubMed] [Google Scholar]
  53. [52]Jacobs, M. V., P. J. Snijders, A. J. van den Brule, T. J. Helmerhorst, C. J. Meijer, and J. M. Walboomers. 1997. A general primer P5+/GP6(+)-mediated PCR enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J. Clin. Microbiol. 35:791-795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. [53]Jeon, S., B. L. Allen-Hoffman, and P. F. Lambert. 1995. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J. Virol. 69:2989-2997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. [54]Jin, X. W., J. Cash, and A. W. Kennedy. 1999. Human papillomavirus typing and the reduction of cervical cancer risk. Cleveland Clin. J. Med. 66:533-539. [DOI] [PubMed] [Google Scholar]
  56. [55]Joyce, J. G., J.-S. Tung, C. T. Przysiecki, J. C. Cook, E. D. Lehman, J. A. Sands, K. U. Jansen, and P. M. Keller. 1999. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J. Biol. Chem. 274:5810-5822. [DOI] [PubMed] [Google Scholar]
  57. [56]Kim, K. Y., L. Blatt, and M. W. Taylor. 2000. The effects of interferon on the expression of human papillomavirus oncogenes. J. Gen. Virol. 81:695-700. [DOI] [PubMed] [Google Scholar]
  58. [57]Kim, J. J., T. C. Wright, and S. J. Goldie. 2002. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 287:2382-2390. [DOI] [PubMed] [Google Scholar]
  59. [58]Kiviat, N. B., and L. A. Koutsky. 1993. Specific human papillomavirus types as the causal agents of most cervical intraepithelial neoplasia: implications for current views and treatment. J. Natl. Cancer Inst. 85:934-935. [DOI] [PubMed] [Google Scholar]
  60. [59]Kleter, B., L. J. van Doorn, L. Schrauwen, A. Molijn, S. Sastrowijoto, J. TerSchegget, J. Lindeman, B. Ter Harmsel, M. Burger, and W. Quint. 1999. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J. Clin. Microbiol. 37:2508-2517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. [60]Koopmanschap, M. A., G. A. van Oortmarssen, H. M. A. van Agt, M. van Ballegooijen, J. D. Habbema, and K. T. Lubbe. 1990. Cervical cancer screening: attendance and cost-effectiveness. Int J. Cancer 45:410-415. [DOI] [PubMed] [Google Scholar]
  62. [61]Kurman, R. J., D. E. Henson, A. L. Herbst, K. L. Noeller, and M. H. Schiffman. 1994. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Workshop. JAMA 271:1866-1869. [PubMed] [Google Scholar]
  63. [62]Lee, J. S. J., P. Wilhelm, L. Kuan, D. G. Ellison, X. Lei, S. Oh, and S. F. Patten. 1997. AutoPap system performance is screening for low prevalence and small cell abnormalities. Acta Cytol. 41:56-64. [DOI] [PubMed] [Google Scholar]
  64. [63]Lee, K. R., R. Ashfaq, G. G. Birdsong, M. E. Corkill, K. M. McIntosh, and S. L. Inhorn. 1997. Comparison of conventional Papanicolaou smears and a fluid-based, thin-layer system for cervical cancer screening. Obstet. Gynecol. 90:278-284. [DOI] [PubMed] [Google Scholar]
  65. [64]Lizard, G, M.-J. Démares-Poulet, P. Roignot, and P. Gambert. 2001. In situ hybridization detection of single-copy human papillomavirus on isolated cells using a catalyzed signal amplification system:GenPoint™. Diagn. Cytopathol. 24:112-116. [DOI] [PubMed] [Google Scholar]
  66. [65]Lonquet, M., S. Beaudenon, and G. Orth. 1996. Two novel genital papillomavirus (HPV) types: HPV68 and HPV70, related to the potentially oncogenic HPV39. J. Clin. Microbiol. 34:738-744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. [66]Lorincz, A. T., W. D. Lancaster, and G. F. Temple. 1986. Cloning and characterization of the DNA of a new human papillomavirus from a woman with dysplasia of the uterine cervix. J. Virol. 58:225-229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. [67]Lorincz, A. T., A. P. Quinn, W. D. Lancaster, and G. F. Temple. 1987. A new type of papillomavirus associated with cancer of the uterine cervix. Virology 159:187-190. [DOI] [PubMed] [Google Scholar]
  69. [68]Lorincz, A. T., G. F. Temple, R. J. Kurman, A. B. Jenson, and W. D. Lancaster. 1987. Oncogenic association of specific human papillomavirus types with cervical neoplasia. JNCI 79:671-677. [PubMed] [Google Scholar]
  70. [69]Lorincz, A. T., A. P. Quinn, M. D. Goldsborough, P. McAllister, and G. F. Temple. 1989. Human papillomavirus type 56: a new virus detected in cervical cancers. J. Gen. Virol. 70:3099-3104. [DOI] [PubMed] [Google Scholar]
  71. [70]Lorincz, A. T., A. P. Quinn, M. D. Goldsborough, B. J. Schmidt, and G. F. Temple. 1989. Cloning and partial DNA sequencing of two new human papillomavirus types associated with condylomas and low-grade cervical neoplasia. J. Virol. 63:2829-2834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. [71]Lorincz, A. T., and R. Reid. 1989. Association of human papillomavirus with gynecological cancer. Curr. Opin. Oncol. 1:123-132. [DOI] [PubMed] [Google Scholar]
  73. [72]Lorincz, A. T., R. Reid, A. B. Jenson, M. D. Greenberg, W. Lancaster, and R. J. Kurman. 1992. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet. Gynecol. 79:328-337. [DOI] [PubMed] [Google Scholar]
  74. [73]Magnusson, P. K. E., P. Lichtenstein, and U. B. Gyllenstein. 2000. Heritability of cervical tumors. Int. J. Cancer 88:698-701. [DOI] [PubMed] [Google Scholar]
  75. [74]Mandelblatt, J. S., W. F. Lawrence, S. M. Womack, D. Jacobson, B. Yi, Y.-T. Hwang, K. Gold, J. Barter, and K. Shah. 2002. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 287:2372-2381. [DOI] [PubMed] [Google Scholar]
  76. [75]Manos, M. M., W. K. Kinney, L. B. Hurley, M. E. Sherman, J. Shieh-Ngai, R. J. Sherman, J. E. Ramsey, B. J. Fetterman, J. S. Hartinger, K. M. McIntosh, G. F. Pawlik, and R. A. Hiatt. 1999. Identifying women with cervical neoplasia: Using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 281:1605-1610. [DOI] [PubMed] [Google Scholar]
  77. [76]Matsukura, T., and M. Sugase. 1990. Molecular cloning of a novel human papillomavirus (type 58) from an invasive cervical carcinoma. Virology 177:833-836. [DOI] [PubMed] [Google Scholar]
  78. [77]Meyers, C., M. G. Frattini, J. B. Hudson, and L. A. Laimins. 1992. Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 257:971-973. [DOI] [PubMed] [Google Scholar]
  79. [78]Moscicki, A. B., J. Palefsky, G. Smith, S. Siboshski, and G. Schoolnik. 1993. Variability of human papillomavirus DNA testing in a longitudinal cohort of young women. Obstst. Gynecol. 82:578-585. [PubMed] [Google Scholar]
  80. [80]Naghashfar, Z. S., N. B. Rosenshein, A. T. Lorincz, J. Buscema, and K. V. Shah. 1987. Characterization of human papillomavirus type 45, a new type 18-related virus of the genital tract. J. Gen. Virol. 68:3073-3079. [DOI] [PubMed] [Google Scholar]
  81. [81]Nobbenhuis, M. A., C. J. Meijer, A. J. van den Brule, L. Rozendaal, F. J. Voorhoost, E. K. Risse, R. H. Verheijen, and T. J. Helmerhorst. 2001. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br. J. Cancer 84:796-801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. [82]Nuovo, G. J., C. P. Crum, E. M. de Villiers, R. U. Levine, and S. J. Silverstein. 1988. Isolation of a novel human papillomavirus (type 51) from a cervical condyloma. J. Virol. 62:1452-1455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. [83]Obalek, S., S. Jablonska, and G. Orth. 1985. HPV-associated intraepithelial neoplasia of external genitalia. Clin. Dermatol. 3:104-113. [DOI] [PubMed] [Google Scholar]
  84. [84]Okamoto, A., C. D. Woodworth, K. Yen, J. Chung, S. Isonishi, T. Nikaido, T. Kiyokawa, H. Seo, Y. Kitahara, K. Ochiai, and T. Tanaka. 1999. Combination therapy with podophyllin and vidarabine for human papillomavirus positive cervical intraepithelial neoplasia. Oncol. Rep. 6:269-276. [DOI] [PubMed] [Google Scholar]
  85. [85]Ostor, A. G. 1993. Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol. Pathol. 12:186-192. [PubMed] [Google Scholar]
  86. [86]Papanicolaou, G. N. 1949. A survey of actualities and potentialities of exfoliative cytology in cancer diagnosis. Ann. Intern. Med. 31:661-674. [DOI] [PubMed] [Google Scholar]
  87. [87]Philips, D. H., and M. NiShé. 1993. Smoking-related DNA adducts in human cervical biopsies. IARC Sci. Publ. 124:327-330. [PubMed] [Google Scholar]
  88. [88]Quint, W. G. V., G. Scholte, L. J. Van Doorn, B. Kleeter, P. H. M. Smits, and J. Lindeman. 2001. Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general SPF10 PCR and HPV genotyping. J. Pathol. 194:51-58. [DOI] [PubMed] [Google Scholar]
  89. [89]Razzaque, A., O. Williams, J. Wang, and J. S. Rhim. 1993. Neoplastic transformation of immortalized human epidermal keratinocytes by two HHV-6 DNA clones. Virology 195:113-120. [DOI] [PubMed] [Google Scholar]
  90. [90]Reid, R., M. Greenberg, A. B. Jenson, M. Husain, J. Willett, Y. Daoud, G. Temple, C. R. Stanhope, A. I. Sherman, G. D. Phibbs, and A. T. Lorincz. 1987. Sexually transmitted papillomavirus infections. 1. The anatomic distribution and pathogenic grade of neoplastic lesions associated with different viral types. Am. J. Obstet. Gynecol. 156:212-222. [DOI] [PubMed] [Google Scholar]
  91. [91]Rho, J., A. Roy-Burman, H. Kim, E. M. de Villiers, T. Matsukura, and J. Choe. 1994. Nucleotide sequence and phylogenetic classification of human papillomavirus type 59. Virology 203:158-161. [DOI] [PubMed] [Google Scholar]
  92. [92]Richart, R. M. 1973. Cervical intraepithelial neoplasia. Pathol. Annu. 3:301-328. [PubMed] [Google Scholar]
  93. [93]Ries, L. A. G., M. P. Eisner, C. L., Kosary, B. F. Hankey, B. A. Miller, L. Glegg, and B. K. Edwards. 2001. SEER cancer statistics review 1973-1998. National Cancer Institute, Bethesda, Md.
  94. [94]Roden, R. B., D. R. Lowy, and J. T. Schiller. 1997. Papillomavirus is resistant to dessication. J. Infect. Dis. 176:1076-1079. [DOI] [PubMed] [Google Scholar]
  95. [95]Romano, N., F. M. Romano, E. Viviano, F. Vitale, M. R. Viaalfrate, A. M. Perna, and F. Bonura. 1996. Rare association of human herpesvirus 6 DNA with human papillomavirus DNA in cervical smears of women with normal and abnormal cytologies. J. Clin. Microbiol. 34:1589-1591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. [96]Ronnett, B. M., M. M. Manos, J. E. Ransley, B. J. Fetterman, W. K. Kinney, L. B. Hurley, J. S. Ngai, R. J. Kurman, and M. E. Sherman. 1999. Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection. Hum. Pathol. 30:816-825. [DOI] [PubMed] [Google Scholar]
  97. [97]Ryan, M. R., J. F. Stastny, R. Remmers, M. A. Pedigo, L. A. Cahill, and W. J. Frable. 1996. PapNet-directed rescreening of cervicovaginal smears: a study of 101 cases of atypical squamous cells of undetermined significance. Am. J. Clin. Pathol. 105:711-718. [DOI] [PubMed] [Google Scholar]
  98. [98]Sapp, M., C. Volpers, M. Muller, and R. E. Streck. 1995. Organization of the major and minor capsid proteins in human papillomavirus type 33 virus-like particles. J. Gen. Virol. 76:2407-2412. [DOI] [PubMed] [Google Scholar]
  99. [99]Sawaya, G. F., K. Kerlikowske, G. Gildengorin, and A. E. Washington. 2000. Incidence of Pap test abnormalities within 3 years of a normal Pap test—United States, 1991-1998. Morb. Mortal. Wkly. Rep. 49:1001-1003. [PubMed] [Google Scholar]
  100. [100]Schiffman, M., R. Herrero, A. Hildesheim, M. E. Sherman, M. Bratti, S. Wacholder, M. Alfaro, M. Hutcinson, J. Morales, M. D. Greenberg, and A. T. Lorincz. 2000. HPV DNA testing in cervical cancer screening. Results from women in a high-risk province of Costa Rica. JAMA 283:87-93. [DOI] [PubMed] [Google Scholar]
  101. [101]Sheets, E. E., N. M. Constantine, S. Sinisco, B. Dean, and E. S. Cibas. 1995. Colposcopically-directed biopsies provide a basis for comparing the accuracy of ThinPrep and Papanicoloau smears. J. Gynecol. Technol. 1:27-34. [Google Scholar]
  102. [102]Shen, C. Y., M. S. Ho, S. F. Chang, M. S. Yen, H. T. Ng, E. S. Huang, and C. W. Wu. 1993. High rate of concurrent genital infections with human cytomegalovirus and human papillomaviruses in cervical cancer patients. J. Infect. Dis. 168:449-452. [DOI] [PubMed] [Google Scholar]
  103. [103]Sherman, M. E., L. J. Mango, D. Kelly, G. Paull, V. Ludin, C. Copeland, D. Solomon, and M. H. Schiffman. 1994. PapNet analysis of reportedly negative smears preceeding the diagnosis of a high grade squamous intraepithelial lesion or carcinoma. Mod. Pathol. 7:578-581. [PubMed] [Google Scholar]
  104. [104]Sherman, M. E., M. H. Schiffman, A. T. Lorincz, M. M. Manos, D. R. Scott, R. J. Kurman, N. B. Kiviat, M. Stoler, A. G. Glass, and B. B. Rush. 1994. Toward objective quality assurance in cervical cytopathology: correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types. Am. J. Clin. Pathol. 102:182-187. [DOI] [PubMed] [Google Scholar]
  105. [105]Shimoda, K., A. T. Lorincz, F. Temple, and W. D. Lancaster. 1988. Human papillomavirus type 52: a new virus associated with cervical neoplasia. J. Gen. Virol. 69:2925-2928. [DOI] [PubMed] [Google Scholar]
  106. [106]Snoeck, R., J. C. Noel, C. Muller, E. De Clercq, and M. Bossens. 2000. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J. Med. Virol. 60:205-209. [DOI] [PubMed] [Google Scholar]
  107. [107]Solomon, D., M. Schiffman, and R. Tarone. 2001. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance. Baseline results from a randomized trial. J. Natl. Cancer Inst. 93:293-299. [DOI] [PubMed] [Google Scholar]
  108. [108]Solomon, D., D. Davey, R. Kurman, A. Moriarity, D. O'Connor, M. Prey, S. Raab, M. Sherman, D. Wilbur, T. Wright, and N. Young. 2002. The 2001 Bethesda System. Terminology for reporting results of cervical cytology. JAMA 287:2114-2119. [DOI] [PubMed] [Google Scholar]
  109. [109]Spitzer, M. 1998. Cervical screening adjuncts: recent advances. Am. J. Obstet. Gynecol. 179:544-556. [DOI] [PubMed] [Google Scholar]
  110. [110]Su, P. F., S. Y. Chiang, C. W. Wu, and F. Y. Wu. 2000. Adeno-associated virus major Rep78 protein disrupts binding of TATA-binding protein to the p97 promoter of human papillomavirus type 16. J. Virol. 74:2459-2465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  111. [111]Swan, D. C., R. A. Tucker, G. Tortolero-Luna, M. F. Mitchell, L. Wideroff, E. R. Unger, R. A. Nisenbaum, W. C. Reeves, and J. P. Icenogle. 1999. Human papilloma (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J. Clin. Microbiol. 37:1030-1034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. [112]Syrjänen, K. J. 1996. Natural history of genital human papillomavirus infections, p. 189-206. In C. Lacey (ed.), Papillomavirus reviews. Leeds University Press, Leeds, United Kingdom.
  113. [113]Syrjänen, S. M., and K. J. Syrjänen. 1999. New concepts on the role of human papillomavirus in cell cycle regulation. Ann. Med. 31:175-187. [DOI] [PubMed] [Google Scholar]
  114. [114]Tewari, K. S., J. A. Taylor, S. Y. Liao P. J. DiSaia, R. A. Burger, B. J. Monk, C. C. Hughes, and L. P. Villarreal. 2000. Development and assessment of a general theory of cervical carcinogenesis utilizing a severe combined immunodeficiency murine-human xenograft model. Gynecol. Oncol. 77:137-148. [DOI] [PubMed] [Google Scholar]
  115. [115]The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. 2000. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions:baseline data from a randomized trial. J. Natl. Cancer Inst. 92:397-402. [DOI] [PubMed] [Google Scholar]
  116. [116]Thomas, M., D. Pim, and L. Banks. 1999. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 18:7690-7000. [DOI] [PubMed] [Google Scholar]
  117. [117]Torrisi, A., A. Del Mistro, G. L. Onnis, F. Merlin, R. Bertorelle, and D. Minucci. 2000. Colposcopy, cytology and HPV testing in HIV-positive and HIV-negative women. Eur. J. Gynecol. Oncol. 21:168-172. [PubMed] [Google Scholar]
  118. [118]VanRanst, M., R. Tachezy, and R. D. Burk. 1996. Human papillomaviruses: a neverending story, p. 1-20. In C. Lacey (ed.), Papillomavirus reviews. Leeds University Press, Leeds, United Kingdom.
  119. [119]Vassilaskos, P., J. Saurel, and R. Rondez. 1999. Direct-to-vial use of the AutoCyte PREP liquid-based preparation for cervical-vaginal specimens in three European laboratories. Acta Cytol. 43:65-68. [DOI] [PubMed] [Google Scholar]
  120. [120]Veress, G., K. Szarka, X.-P. Dong, L. Gergely, and H. Pfister. 1999. Functional significance of sequence variation in the E2 gene and the long control region of human papillomavirus type 16. J. Gen. Virol. 80:1053-1043. [DOI] [PubMed] [Google Scholar]
  121. [121]Villa, L. L. 1997. Human papillomaviruses and cervical cancer. Adv. Cancer Res. 71:321-341. [DOI] [PubMed] [Google Scholar]
  122. [122]Volpers, C., and R. E. Streek. 1991. Genome organization and nucleotide sequence of human papillomavirus type 39. Virology 181:419-423. [DOI] [PubMed] [Google Scholar]
  123. [123]Walboomers, J. M. M., and C. J. L. M. Meijer. 1997. Do HPV-negative cervical carcinomas exist? J. Pathol. 181:253-254. [DOI] [PubMed] [Google Scholar]
  124. [124]Walboomers, J. M. M., M. V. Jacobs, M. M. Manos, F. X. Bosch, J. A. Kummer, K. V. Shah, P. J. F. Snijders, J. Peto, C. J. L. M. Meijer, and N. Munoz. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:12-19. [DOI] [PubMed] [Google Scholar]
  125. [125]Wright, T. C., and R. T. Kurman. 1994. A critical review of the morphologic classification system of preinvasive lesions of the cervix: the scientific basis for shifting the paradigm. Papillomavirus Rep. 5:175-182. [Google Scholar]
  126. [126]Wright, T. C., L. Denny, L. Kuhn, A. Pollack, and A. Lorincz. 2000. HPV DNA Testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 283:81-86. [DOI] [PubMed] [Google Scholar]
  127. [127]Wright, T. C., J. T. Cox, L. S. Massad, L. B. Twiggs, and E. J. Wilkinson. 2002. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 287:2120-2129. [DOI] [PubMed] [Google Scholar]
  128. [128]Yang, X., G. Jin, Y. Nakao, M. Rahimtula, M. M. Pater, and A. Pater. 1996. Malignant transformation of HPV-16 immortalized human endocervical cells by cigarette smoke condensate and characterization of multistage carcinogenesis. Int J. Cancer 65:338-344. [DOI] [PubMed] [Google Scholar]
  129. [129]Yoshinouchi, M., A. Hongo, K. Nakamura, J. Kodama, S. Itoh, H. Sakai, and T. Kudo. 1999. Analysis by multiplex PCR of the physical status of human papillomavirus type 16 DNA in cervical cancers. J. Clin. Microbiol. 37:3514-3517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  130. [130]Zerbini, M., S. Venturoli, M. Cricca, G. Gallinella, P. De Simone, S. Costa, D. Santini, and M. Musiani. 2001. Distribution and viral load of type specific HPVs in different cervical lesions as detected by PCR-ELISA. J. Clin. Pathol. 54:377-380. [DOI] [PMC free article] [PubMed] [Google Scholar] zur Hausen, H. 1982. Human genital cancer: synergism between two virus infections and or synergism between a virus infection and initiating events? Lancet ii:1370-1372. [DOI] [PubMed] [Google Scholar] zur Hausen, H. 1996. Papillomavirus infections - a major cause of human cancers. Biochim. Biophys. Acta 1288:55-78. [DOI] [PubMed] [Google Scholar] zur Hausen, H. 1999. Papillomaviruses in human cancers. Proc. Assoc. Am. Physicians 111:581-587. [DOI] [PubMed] [Google Scholar]

Cited by

Sorted by citations

Authors
Burd, E. M.
Affiliations
Henry Ford Hospital (US)
Corresponding author
Burd, Eileen M.
ORCID
Burd, Eileen M.
Venue
Clinical Microbiology Reviews
Publisher
American Society for Microbiology
Published
2003-01
Volume
16
Issue
1
Pages
1-17
ISSN
  • 0893-8512 (ISSN-L)
  • 1098-6618
DOI
10.1128/cmr.16.1.1-17.2003
PMC
PMC145302
OpenAlex
W2131255017
Cited by
2,420
References
1
Citations by year
2026: 106 · 2025: 219 · 2024: 218 · 2023: 211 · 2022: 197 · 2021: 229 · 2020: 213 · 2019: 166 · 2018: 148 · 2017: 108 · 2016: 102 · 2015: 94 · 2014: 72 · 2013: 69 · 2012: 37
FWCI
3.41
Type
journal article
Language
en
Open access
Licence
journals.asm.org/non-commercial-tdm-license (tdm)
Locations
  • Clinical Microbiology Reviews (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
Keywords
human papillomavirus, cervical cancer, high-risk HPV, cervical precancerous lesions, HPV testing, cervical cytology screening, colposcopy, HPV genotyping, cervical cancer prevention
MeSH terms
Uterine Cervical Neoplasms, DNA, Viral, Female, Humans, Papillomaviridae

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review